Meet MPI at SACHS Immuno-Oncology BD&L, Chicago; ASCO, American Society of Clinical Oncology, Chicago; BIO in San Francisco

2016-06-02

Company News

JUNE 3rd:

APO010 *Oncology Ventures FAS ligand, immuno-Oncology drug to be presented at SACHS ASSOCIATES 2nd Immuno-Oncology BD&L and Investment Forum. Hyatt Magnificent Mile, Chicago, USA.
The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. 
We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

*Oncology Venture is a spinout from and the drug development arm of MPI

JUNE 3-7:
ASCO, American Society of Clinical Oncology, ANNUAL MEETING. McCormick Place, Chicago, Illinois, USA.
MPI has a booth # 23111 as well as a numerous of Face to Face meetings arranged.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer.
The ASCO Annual Meeting is considered the premiere international forum for the presentation of scientific research and state-of-the-art education in clinical oncology. The five-day event attracts 30,000 attendees from around the world. Clinical trial results and updates presented at ASCO's Annual Meeting represent the significant progress made each year in the fight against cancer.

JUNE 6-9: 
BIO International Convention. Moscone Center, San Francisco, CA, USA
The BIO International Convention returns to the birthplace of biotech, San Francisco, California for 2016! The Bay Area region continues to grow and advance biomedical innovation while continuing to offer programs and services to support new medical advances. This event covers a wide spectrum of life science and application areas including drug discovery, bio-manufacturing, genomics, biofuels, nanotechnology and cell therapy.

The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships.

For additional information about MPI:

Peter Buhl Jensen, VD
Telephone: +45 21 60 89 22
E-mail: pbj@medical-prognosis.com
Ulla Hald Buhl, Chief Investor Relations and Communications
Telephone: +45 21 70 10 49
E-mail: uhb@medical-prognosis.com

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Danmark

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereasthe messengerRNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.